[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2016008910A - Compuestos de fenil-triazolo-piridina. - Google Patents

Compuestos de fenil-triazolo-piridina.

Info

Publication number
MX2016008910A
MX2016008910A MX2016008910A MX2016008910A MX2016008910A MX 2016008910 A MX2016008910 A MX 2016008910A MX 2016008910 A MX2016008910 A MX 2016008910A MX 2016008910 A MX2016008910 A MX 2016008910A MX 2016008910 A MX2016008910 A MX 2016008910A
Authority
MX
Mexico
Prior art keywords
triazolo
phenyl
group
pyridine compounds
och3
Prior art date
Application number
MX2016008910A
Other languages
English (en)
Inventor
Hamdouchi Chafiq
Maiti Pranab
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2016008910A publication Critical patent/MX2016008910A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula I abajo: en donde R1 se selecciona a partir del grupo que consiste de H, CH3, CN, -CH2CN, -C(CH3)2CN, F, CI y Br; R2 se selecciona a partir del grupo que consiste de H, -O(alquileno C1-C3)R4, -CH2CN, CN, - OCH3, CF2, -C(CH3)2CN, -C(CH3)2, -S(O)2CH3, -S(O)2NH2 y -OCF2; R3 se selecciona a partir del grupo que consiste de H, CH3 y -OCH3 y R4 se selecciona a partir del grupo que consiste de H, -C(CH3)2CN, -OCH3, -S(O)2CH3, CN y -C(CH3)2OH; o una sal farmacéutica del mismo, métodos para tratar diabetes tipo dos usando el compuesto y un proceso para preparar el compuesto. (ver Fórmula).
MX2016008910A 2014-01-10 2015-01-06 Compuestos de fenil-triazolo-piridina. MX2016008910A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925802P 2014-01-10 2014-01-10
PCT/US2015/010291 WO2015105786A1 (en) 2014-01-10 2015-01-06 Phenyl-triazolo-pyridine compounds

Publications (1)

Publication Number Publication Date
MX2016008910A true MX2016008910A (es) 2016-10-04

Family

ID=52440835

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008910A MX2016008910A (es) 2014-01-10 2015-01-06 Compuestos de fenil-triazolo-piridina.

Country Status (12)

Country Link
US (1) US9617263B2 (es)
EP (1) EP3092241B1 (es)
JP (1) JP6211200B2 (es)
KR (1) KR20160095117A (es)
CN (1) CN105873929B (es)
AU (1) AU2015204923A1 (es)
BR (1) BR112016013874A2 (es)
CA (1) CA2931822A1 (es)
EA (1) EA201691071A1 (es)
ES (1) ES2653425T3 (es)
MX (1) MX2016008910A (es)
WO (1) WO2015105786A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2931817A1 (en) 2014-01-10 2015-07-16 Eli Lilly And Company Isopropyl triazolo pyridine compounds
PL3737470T3 (pl) 2018-01-08 2023-05-08 Celon Pharma S.A. Pochodne kwasu 3-fenylo-4-heksynowego jako agoniści gpr40
TWI796596B (zh) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
EP3781556A1 (en) 2018-04-19 2021-02-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US20220281866A1 (en) * 2019-07-19 2022-09-08 Janssen Pharmaceutica Nv 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN115317484B (zh) * 2022-08-26 2023-07-18 北京箭牧科技有限公司 Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用
CN115671105B (zh) * 2022-11-22 2023-10-27 北京箭牧科技有限公司 Ly2922470在制备预防或治疗肾脏疾病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
ES2433466T3 (es) 2004-02-27 2013-12-11 Amgen, Inc Compuestos, composiciones farmacéuticas y métodos para su uso en el tratamiento de trastornos metabólicos
US8530413B2 (en) * 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
CN104245696A (zh) 2012-02-07 2014-12-24 凯诺斯医药公司 作为1型二酰基甘油o-酰基转移酶的抑制剂的化合物
TW201609722A (zh) * 2013-12-13 2016-03-16 美國禮來大藥廠 新穎三唑并吡啶化合物
CA2931817A1 (en) 2014-01-10 2015-07-16 Eli Lilly And Company Isopropyl triazolo pyridine compounds

Also Published As

Publication number Publication date
CA2931822A1 (en) 2015-07-16
US20170029420A1 (en) 2017-02-02
US9617263B2 (en) 2017-04-11
CN105873929A (zh) 2016-08-17
EA201691071A1 (ru) 2016-11-30
AU2015204923A1 (en) 2016-06-09
CN105873929B (zh) 2018-04-06
JP6211200B2 (ja) 2017-10-11
JP2017503800A (ja) 2017-02-02
KR20160095117A (ko) 2016-08-10
WO2015105786A1 (en) 2015-07-16
ES2653425T3 (es) 2018-02-07
BR112016013874A2 (pt) 2017-08-08
EP3092241B1 (en) 2017-10-04
EP3092241A1 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
MX2016008910A (es) Compuestos de fenil-triazolo-piridina.
PH12019501941A1 (en) Jak inhibitors containing a 4-membered heterocyclic amide
MX2019012942A (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
PH12017501016A1 (en) Triazolopyrimidine compounds and uses thereof
MX2017008417A (es) Procedimientos para preparar inhibidores de cinasa 1 reguladora de señal de apoptosis (ask1).
NZ732657A (en) Picolinamides with fungicidal activity and other related compounds
PH12016501440A1 (en) Novel heterocyclic compounds
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
MA40301B1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
AR105668A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
EA201691150A1 (ru) Соединения изопропилтриазолопиридина
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
MA40302B1 (fr) Dérivés de carbazole
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
MX2016007567A (es) Un nuevo compuesto de triazolo-piridina.
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX2018005133A (es) Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos.
MX2016012719A (es) Uso de compuesto heterociclicos para controlar nematodos.
MX2019007629A (es) Proceso para la preparacion de un derivado de 2-piridiletilcarboxamida.
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
MX2019001393A (es) 1-hidroximetil-1,2,2,6-tetrametil-ciclohexano y sus derivados y su uso como productos quimicos aromaticos.
MY184366A (en) Pyrazines modulators of gpr6
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
EA201691265A1 (ru) Соединения агонисты gpr142
PH12017501560A1 (en) Tetrahydropyranyl benzamide derivatives